Charles River Laboratories International, Inc.

CRL · New York Stock Exchange · USD

353,34USD

+15,82 (+4,69 %)Stand 9. Nov., 21:00

Vorbörslich359,30+5,96 (+1,69 %)7:46 ET

Vortag 337,52

Kennzahlen

Eröffnung
344,32
Vortag
337,52
Tagesspanne
342,00 – 358,77
52 Wochen
146,20 – 379,63
Volumen
943.084
Ø Volumen
1,01 Mio.
Börsenwert
16,93 Mrd. $
KGV
346,4
Gewinn je Aktie (TTM)
0,91
Dividendenrendite
0,0 %
Beta
1,3
Nächste Zahlen
17. Feb. 2027

Finanzen

USDFY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz4,02 Mrd.4,05 Mrd.4,13 Mrd.3,98 Mrd.3,54 Mrd.
Herstellungskosten2,79 Mrd.2,72 Mrd.2,63 Mrd.2,51 Mrd.2,21 Mrd.
Bruttogewinn1,23 Mrd.1,33 Mrd.1,5 Mrd.1,46 Mrd.1,33 Mrd.
Forschung und Entwicklung00000
Vertrieb und Verwaltung743,07 Mio.751 Mio.747,86 Mio.665,1 Mio.619,92 Mio.
Operatives Ergebnis507,84 Mio.227,35 Mio.617,26 Mio.650,98 Mio.589,86 Mio.
EBITDA410,84 Mio.581,14 Mio.1,03 Mrd.986,15 Mio.820,16 Mio.
Nettogewinn−144,34 Mio.10,3 Mio.474,62 Mio.486,23 Mio.390,98 Mio.
Gewinn je Aktie (verwässert)-2,910,209,229,487,60

Umsatz nach Segment

Produkte · FY 2025

  • Discovery and Safety Assessment2,4 Mrd. $59,84 %
    −1,97 %
  • Research Models and Services846,08 Mio. $21,07 %
    +2,01 %
  • Manufacturing Support766,41 Mio. $19,09 %
    −0,38 %

Anteil · ggü. Vorjahr (FY 2024)

Regionen · FY 2025

  • UNITED STATES2,14 Mrd. $54,22 %
    −4,38 %
  • Europe1,1 Mrd. $27,91 %
    +2,28 %
  • CANADA501,03 Mio. $12,68 %
    +3,93 %
  • Asia Pacific205,02 Mio. $5,19 %
    +4,10 %

Anteil · ggü. Vorjahr (FY 2024)

Bewertung

Letzte 12 Monate

KGV
346,4
Kurs-Umsatz-Verhältnis
4,3
Kurs-Buchwert-Verhältnis
5,2
PEG
-3,9
Bruttomarge
32,9 %
Operative Marge
14,1 %
Nettomarge
1,0 %
Verschuldungsgrad
0,9
EV/EBITDA
66,8
Eigenkapitalrendite
1,3 %
Kapitalrendite (ROIC)
−3,8 %
Free-Cashflow-Rendite
2,4 %
FY 2025FY 2024FY 2023FY 2022FY 2021
Bruttomarge30,5 %32,9 %36,4 %36,8 %37,7 %
Operative Marge12,6 %5,6 %14,9 %16,4 %16,7 %
Nettomarge−3,6 %0,3 %11,5 %12,2 %11,0 %
KGV-70,0930,825,522,847,5
Kurs-Umsatz-Verhältnis2,52,42,92,85,2
Kurs-Buchwert-Verhältnis3,22,83,43,77,3
Verschuldungsgrad1,00,80,91,01,3
Liquidität 3. Grades1,31,41,51,31,2
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert12,95 Mrd.12,09 Mrd.14,9 Mrd.13,94 Mrd.21,53 Mrd.
EV/EBITDA31,520,814,414,126,2
Eigenkapitalrendite−4,6 %0,3 %13,2 %16,3 %15,4 %
Kapitalrendite (ROIC)8,4 %0,9 %7,1 %7,9 %8,1 %
Free-Cashflow-Rendite5,1 %5,2 %3,0 %2,7 %2,9 %

Wachstum

FY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz−0,9 %−1,9 %+3,9 %+12,3 %+21,1 %
Bruttogewinn−8,0 %−11,4 %+2,7 %+9,6 %+24,3 %
Operatives Ergebnis+123,4 %−63,2 %−5,2 %+10,4 %+36,3 %
Nettogewinn−1.501,7 %−97,8 %−2,4 %+24,4 %+7,3 %
Gewinn je Aktie−1.555,0 %−97,8 %−2,7 %+24,7 %+5,6 %
Freier Cashflow+3,4 %+37,3 %+23,9 %−44,6 %+40,0 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen · Buy

  • 1Stark kaufen
  • 27Kaufen
  • 9Halten
  • 0Verkaufen
  • 0Stark verkaufen

Kursziel

308,36

Durchschnitt · −12,73 %

Tief 219,00Aktuell 353,34Hoch 357,00

Schätzungen

FY 2026FY 2027FY 2028
Umsatz (Ø)3,94 Mrd.4,04 Mrd.4,27 Mrd.
Umsatz (Tief – Hoch)3,92 Mrd. – 3,97 Mrd.3,96 Mrd. – 4,1 Mrd.4,09 Mrd. – 4,33 Mrd.
Gewinn je Aktie (Ø)11,4512,8914,37
Gewinn je Aktie (Tief – Hoch)11,24 – 11,6012,19 – 13,1610,60 – 18,59
Analysten9105

Letzte Änderungen

  • Barclays5. Nov. 2026Overweight
  • RBC Capital5. Nov. 2026Outperform
  • UBS5. Nov. 2026Buy
  • Evercore ISI Group5. Nov. 2026Outperform
  • Morgan Stanley13. Okt. 2026Overweight
  • Jefferies28. Sept. 2026Buy
  • TD Cowen25. Sept. 2026Buy
  • Deutsche Bank25. Sept. 2026Buy

Quartalszahlen

Nächste Zahlen: 17. Feb. 2027
Nov. 2026Aug. 2026Mai 2026Feb. 2026Nov. 2025Aug. 2025Mai 2025Feb. 2025
Gewinn je Aktie · Erwartet2,972,741,962,332,322,502,062,50
Gewinn je Aktie · Tatsächlich3,093,022,062,392,433,122,342,66
Abweichung+4,04 %+10,22 %+5,10 %+2,58 %+4,74 %+24,80 %+13,59 %+6,40 %
Umsatz · Tatsächlich982,73 Mio.1 Mrd.995,83 Mio.994,23 Mio.1 Mrd.1,03 Mrd.984,17 Mio.1 Mrd.

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

–

Eigentümer

Institutionen

Q2 2026 · 13F

Anteil institutioneller Investoren
118,20 %
Investoren mit 13F-Meldung
585

Größte Investoren

  • FMR LLC8,74 %4,24 Mio.
  • BLACKROCK, INC.7,83 %3,8 Mio.
  • VANGUARD CAPITAL MANAGEMENT LLC6,50 %3,15 Mio.
  • INVESCO LTD.6,16 %2,98 Mio.
  • HARRIS ASSOCIATES L P4,62 %2,24 Mio.
  • VANGUARD PORTFOLIO MANAGEMENT LLC4,56 %2,21 Mio.
  • ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC3,93 %1,91 Mio.
  • STATE STREET CORP3,81 %1,86 Mio.

Insider-Geschäfte

  • Knell Michael Gunnar6. Nov. 2026 · officer: SVP, Finance and CAOVerkauf649 Aktien · 313,02
  • FOSTER JAMES C22. Okt. 2026 · directorKauf24.042 Aktien · 244,41
  • FOSTER JAMES C22. Okt. 2026 · directorVerkauf24.042 Aktien · 350,00
  • FOSTER JAMES C22. Okt. 2026 · directorVerkauf24.042 Aktien · 244,41
  • Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentKauf2156 Aktien · 244,41
  • Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentVerkauf2156 Aktien · 344,41
  • Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentVerkauf2156 Aktien · 244,41
  • Parisotto Shannon M5. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentKauf981 Aktien · 208,44

Vergleichbare Unternehmen

Über das Unternehmen

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Führung

  • Birgit GirshickCEO & Director
  • Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy
  • Victoria L. CreamerCorporate Executive Vice President & Chief People Officer
  • Glenn G. ColemanCorporate Executive Vice President & Chief Financial Officer
  • Michael Gunnar KnellCorporate Senior Vice President & Chief Accounting Officer
  • Brian F. BathgateCorporate Senior Vice President of European Safety Assessment
CEO
Birgit Girshick
Mitarbeitende
19.000
Hauptsitz
Wilmington, MA, US
Sektor
Healthcare
Branche
Medical - Diagnostics & Research
Börsengang
23. Juni 2000
Website
criver.com

Nachrichten

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.